Kronos Bio Overview
- Year Founded
-
2017
- Status
-
Acquired/Merged
- Employees
-
8
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$59.7M
Kronos Bio General Information
Description
Operator of a clinical-stage biopharmaceutical company intended to discover and develop novel cancer therapeutics. The company specializes in the discovery and development of small-molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.
Contact Information
Website
www.kronosbio.comCorporate Office
- 301 Binney Street
- 2nd Floor East
- Cambridge, MA 02142
- United States
Corporate Office
- 301 Binney Street
- 2nd Floor East
- Cambridge, MA 02142
- United States
Kronos Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 01-May-2025 | $59.7M | Completed | Generating Revenue | ||
| 5. IPO | 09-Oct-2020 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 24-Aug-2020 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 18-Jul-2019 | Completed | Generating Revenue | |||
| 2. Seed Round | 23-May-2018 | $18M | $18M | Completed | Generating Revenue | |
| 1. Seed Round | 02-Jun-2017 | Completed | Generating Revenue |
Kronos Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed |
Kronos Bio Comparisons
Industry
Financing
Details
Kronos Bio Competitors (41)
One of Kronos Bio’s 41 competitors is Inhibrx, a Formerly VC-backed company based in La Jolla, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inhibrx | Formerly VC-backed | La Jolla, CA | ||||
| Cullgen | Formerly VC-backed | San Diego, CA | ||||
| Adimab | Venture Capital-Backed | Lebanon, NH | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA | ||||
| Sareum Holdings | Corporation | Cambridge, United Kingdom |
Kronos Bio Patents
Kronos Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026222092-A1 | Lysine acetyl-transferase inhibitor solid form compositions | Pending | 15-Apr-2025 | ||
| WO-2026222104-A1 | Lysine acetyl-transferase inhibitor solid form compositions | Pending | 15-Apr-2025 | ||
| EP-4836782-A1 | Lysine acetyltransferase inhibitors | Pending | 05-Jan-2024 | ||
| WO-2025147670-A1 | Lysine acetyltransferase inhibitors | Inactive | 05-Jan-2024 | ||
| EP-4795045-A1 | Lysine acetyltransferase inhibitors | Pending | 16-Oct-2023 | C07D471/04 |
Kronos Bio Signals
Kronos Bio Former Investors (22)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| Bellco Capital | PE/Buyout | Minority | ||
| BlackRock | Asset Manager | Minority | ||
| Casdin Capital | Venture Capital | Minority | ||
| Citadel Enterprise Americas | Hedge Fund | Minority |
Kronos Bio Investments (2)
Kronos Bio’s most recent deal was a Early Stage VC with RabbitX for . The deal was made on 07-Oct-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| RabbitX | 07-Oct-2021 | Early Stage VC | Other Financial Services | ||
| Gilead (SYK Inhibitor Portfolio) | 16-Jul-2020 | Corporate Asset Purchase | Buildings and Property |
Kronos Bio ESG
Risk Overview
Risk Rating
Updated March, 31, 2026
38.32 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Pharmaceuticals
Subindustry
of 406
Rank
Percentile
Kronos Bio FAQs
-
When was Kronos Bio founded?
Kronos Bio was founded in 2017.
-
Where is Kronos Bio headquartered?
Kronos Bio is headquartered in Cambridge, MA.
-
What is the size of Kronos Bio?
Kronos Bio has 8 total employees.
-
What industry is Kronos Bio in?
Kronos Bio’s primary industry is Biotechnology.
-
Is Kronos Bio a private or public company?
Kronos Bio is a Private company.
-
What is the current valuation of Kronos Bio?
The current valuation of Kronos Bio is .
-
What is Kronos Bio’s current revenue?
The current revenue for Kronos Bio is .
-
How much funding has Kronos Bio raised over time?
Kronos Bio has raised $528M.
-
Who are Kronos Bio’s investors?
, Bellco Capital, BlackRock, Casdin Capital, and Citadel Enterprise Americas are 5 of 22 investors who have invested in Kronos Bio.
-
Who are Kronos Bio’s competitors?
Inhibrx, Cullgen, Adimab, Sangamo Therapeutics, and Sareum Holdings are some of the 41 competitors of Kronos Bio.
-
When was Kronos Bio acquired?
Kronos Bio was acquired on 01-May-2025.
-
Who acquired Kronos Bio?
Kronos Bio was acquired by Concentra Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process